Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median...

Benzinga · Jun 28 04:03

Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median DFS Endpoint as of the May 24 Cutoff Date.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median...

Elicio Therapeutics Shares Are Trading Lower After the Company Announced Preliminary Disease-free Survival Analysis From the Phase 1a Study of ELI-002 7P, Showing Patients Receiving ELI-002 7P at a Dose of 4.9mg AMP-peptide Had yet to Reach the Median DFS Endpoint as of the May 24 Cutoff Date.

Risk Disclaimer